Trials / Terminated
TerminatedNCT05799183
A SHR-1210 BE Study on Healthy Subjects
A Bioequivalence Study of SHR-1210 in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the bioequivalence of SHR-1210 before and after process changes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1210 | Subjects will receive treatment SHR-1210 before process changes 20 mg |
| DRUG | SHR-1210 | Subjects will receive treatment SHR-1210 after process changes 20 mg |
Timeline
- Start date
- 2023-07-04
- Primary completion
- 2023-10-12
- Completion
- 2023-10-12
- First posted
- 2023-04-05
- Last updated
- 2024-12-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05799183. Inclusion in this directory is not an endorsement.